Join
Live feed
·
PRReleasevia Quantisnow
MeiraGTx Holdings plc logo

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

ByQuantisnow·Wall Street's wire, on your screen.
MGTX· MeiraGTx Holdings plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MGTX (MeiraGTx Holdings plc) and more on Quantisnow.

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia | Quantisnow